Many investigators have evaluated the effects of myostatin inhibition in muscle disease models such as cancer cachexia, CKD, Duchenne muscular dystrophy (DMD), and amyotrophic lateral sclerosis [54]. The gene discussed is MSTN; the disease is chronic kidney disease.